Abstract
Coronary atherosclerosis leading to ischemic artery disease is one of the etiological factors to develop heart failure (HF). This study aimed to investigate potential biomarkers for discriminating HF in atherosclerotic patients. This study included 40 consecutive atherosclerotic patients who underwent angiography. Concentrations of B-type natriuretic peptide (BNP), fibronectin type III domain containing 5 (FNDC5), and Phosphodiesterase 9A (PDE9A) were measured in 20 atherosclerotic patients with HF symptoms/signs and 20 without HF symptoms/signs. Circulating BNP levels were elevated, while FNDC5 levels were reduced in atherosclerotic patients with HF symptoms/signs compared to those without HF symptoms/signs. Pearson correlation analysis showed a significant correlation between FNDC5 and BNP. Receiver Operating Characteristics analysis indicated that both FNDC5 and BNP were able to discriminate HF in atherosclerotic patients. Our findings suggest that FNDC5, along with BNP, has independent value as a biomarker for discriminating HF in patients with coronary atherosclerosis.
Graphical Abstract
Similar content being viewed by others
Data Availability
Patients’ data are available upon reasonable request.
Abbreviations
- AUC:
-
Areas under the curve
- BNP:
-
B-type natriuretic peptide
- CAD:
-
Coronary artery disease
- CI:
-
Confidence interval
- FNDC5:
-
Fibronectin type III domain containing 5
- HF:
-
Heart failure
- HFpEF:
-
Heart failure patients with preserved ejection fraction
- LVEF:
-
Left ventricular ejection fraction
- NYHA:
-
New York Heart Association
- PDE9A:
-
Phosphodiesterase 9A
- ROC:
-
Receiver operating characteristics
References
GBD 2017 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7.
Fernandes VRS, Cheng S, Lima JAC. Atherosclerosis imaging and heart failure. Heart Fail Rev. 2006;11:279–88. https://doi.org/10.1007/s10741-006-0229-7.
Jain CC, Borlaug BA. Performance and interpretation of invasive hemodynamic exercise testing. Chest. 2020;158:2119–29. https://doi.org/10.1016/j.chest.2020.05.552.
Gevaert AB, Kataria R, Zannad F, et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022;108:1342–50. https://doi.org/10.1136/heartjnl-2021-319605.
Adamson PD, Hunter A, Madsen DM, et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes. 2018;11:e004227. https://doi.org/10.1161/circoutcomes.117.004227.
Cwikiel J, Seljeflot I, Fagerland, et al. High-sensitive cardiac Troponin T and exercise stress test for evaluation of angiographically significant coronary disease. Int J Cardiol. 2019;287:1–6. https://doi.org/10.1016/j.ijcard.2019.04.019.
Meijers WC, Bayes-Genis A, Mebazaa A. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail. 2021;23:1610–32. https://doi.org/10.1002/ejhf.2346.
Yasue H, Yoshimura M, Sumida H. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203. https://doi.org/10.1161/01.cir.90.1.195.
Zhang X, Hu C, Wu HM, et al. Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target. Acta Pharmacol Sin. 2021;42:1390–400. https://doi.org/10.1038/s41401-020-00557-5.
Ritterhoff J, Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat Rev Cardiol. 2023. https://doi.org/10.1038/s41569-023-00887-x. (Online ahead of print).
Lee DI, Zhu G, Sasaki T, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015;519:472–6. https://doi.org/10.1038/nature14332.
Cao RY, Zheng H, Hong Y, et al. Cardiac rehabilitation with targeted intensity improves cardiopulmonary functions accompanying with reduced copeptin level in patients with coronary artery disease. J Cardiovasc Transl Res. 2021;14:317–26. https://doi.org/10.1007/s12265-020-10055-y.
McDonagh TA, Metra M, Adamo M, et al. ESC scientific document group, 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e895–1032. https://doi.org/10.1161/CIR.0000000000001063.
Korta P, Pocjec E, Mazur-Bialy A. Irisin as a multifunctional protein: implications for health and certain diseases. Medicina. 2019;55:485. https://doi.org/10.3390/medicina55080485.
Benomar K, Espiard S, Loyer C, Jannin A, Vantyghem MC. Atrial natriuretic hormones and metabolic syndrome: recent advances. Presse Med. 2018;47:116–24. https://doi.org/10.1016/j.lpm.2017.12.002.
Abd EI-Mottaleb NA, Galal HM, EI Maghraby KM, Gadallah AI. Serum irisin level in myocardial infarction patients with or without heart failure. Can J Physiol Pharmacol. 2019;97:932–8. https://doi.org/10.1139/cjpp-2018-0736.
Matsuo Y, Gleitsmann K, Mangner N, et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle. 2015;6:62–72. https://doi.org/10.1002/jcsm.12006.
Lecker SH, Zavin A, Cao P, et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail. 2012;5:812–8. https://doi.org/10.1161/CIRCHEARTFAILURE.112.969543.
Yu Q, Kou W, Xu X, et al. FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci (Lond). 2019;133:611–27. https://doi.org/10.1042/CS20190016.
Maak S, Norheim F, Drevon CA, Erickson HP. Progress and challenges in the biology of FNDC5 and Irisin. Endocr Rev. 2021;42:436–56. https://doi.org/10.1210/endrev/bnab003.
Cao RY, Zheng H, Redfearn D, Yang J. FNDC5: a novel player in metabolism and metabolic syndrome. Biochimie. 2019;158:111–6. https://doi.org/10.1016/j.biochi.2019.01.001.
Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation. 2019;140:353–65. https://doi.org/10.1161/circulationaha.118.039136.
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–70. https://doi.org/10.1161/circulationaha.118.034646.
Hashemi D, Mende M, Trippel TD, et al. Evaluation of the HFA-PEFF score: results from the prospective DIAST-CHF cohort. ESC Heart Fail. 2022;9:4120–8. https://doi.org/10.1002/ehf2.14131.
Wijk SS, Aizpurua AB, Rocca HB, et al. The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:838–40. https://doi.org/10.1002/ejhf.2019.
Pocock SJ, Ferreira JP, Packer M, et al. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24:1869–78. https://doi.org/10.1002/ejhf.2607.
Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J. 2005;26:241–9. https://doi.org/10.1093/eurheartj/ehi036.
Acknowledgements
All authors are grateful to young physicians including residents from the Department of Cardiology, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University for their dedications to collect clinical data.
Funding
This work was supported by the National Natural Science Foundation of China [grant number 81672260 for RYC] and Xuhui Healthcare System Peak Discipline Construction Funding Project of Shanghai [grant number SHXHZDXK202305 for HZ & PM]. The funding sources were not involved in study design; in the analysis and interpretation of data; and in the decision to submit the article for publication.
Author information
Authors and Affiliations
Contributions
Hongchao Zheng and Richard Y. Cao conceptualized, revised, and proofread the manuscript; Hongchao Zheng and Yuntao Zheng prepared the draft; Wei Huang, Lingling Jiang, Peizhi Miao, and Ning Zhu collected and analyzed data; Siyu Liu analyzed data and prepared artwork.
Corresponding author
Ethics declarations
Human Subjects/Informed Consent Statement
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (The Ethics Committee of Shanghai Xuhui Central Hospital, Shanghai, China) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from every patient for being included in the study.
Conflict of Interest
The authors declare that there is no conflict of interests.
Additional information
Associate Editor Junjie Xiao oversaw the review of this article
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zheng, H., Zheng, Y., Huang, W. et al. Exploration of the Potential Biomarker FNDC5 for Discriminating Heart Failure in Patients with Coronary Atherosclerosis. J. of Cardiovasc. Trans. Res. (2024). https://doi.org/10.1007/s12265-024-10489-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12265-024-10489-8